Bangladesh · Delayed Price · Currency is BDT Advent Pharma Statistics
Total Valuation
Advent Pharma has a market cap or net worth of BDT 1.34 billion. The enterprise value is 1.42 billion.
| Market Cap | 1.34B |
| Enterprise Value | 1.42B |
Important Dates
The next estimated earnings date is Thursday, January 28, 2027.
| Earnings Date | Jan 28, 2027 |
| Ex-Dividend Date | Nov 23, 2026 |
Share Statistics
Advent Pharma has 93.13 million shares outstanding. The number of shares has decreased by -0.28% in one year.
| Current Share Class | 93.13M |
| Shares Outstanding | 93.13M |
| Shares Change (YoY) | -0.28% |
| Shares Change (QoQ) | +6.75% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 34.29.
| PE Ratio | 34.29 |
| Forward PE | n/a |
| PS Ratio | 3.29 |
| PB Ratio | 0.84 |
| P/TBV Ratio | 0.84 |
| P/FCF Ratio | 612.17 |
| P/OCF Ratio | 91.99 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.38, with an EV/FCF ratio of 647.34.
| EV / Earnings | 35.95 |
| EV / Sales | 3.48 |
| EV / EBITDA | 11.38 |
| EV / EBIT | 22.36 |
| EV / FCF | 647.34 |
Financial Position
The company has a current ratio of 2.72, with a Debt / Equity ratio of 0.05.
| Current Ratio | 2.72 |
| Quick Ratio | 1.36 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 0.62 |
| Debt / FCF | 35.37 |
| Interest Coverage | 5.33 |
Financial Efficiency
Return on equity (ROE) is 2.51% and return on invested capital (ROIC) is 2.90%.
| Return on Equity (ROE) | 2.51% |
| Return on Assets (ROA) | 1.99% |
| Return on Invested Capital (ROIC) | 2.90% |
| Return on Capital Employed (ROCE) | 3.50% |
| Weighted Average Cost of Capital (WACC) | 6.05% |
| Revenue Per Employee | 1.27M |
| Profits Per Employee | 122,712 |
| Employee Count | 317 |
| Asset Turnover | 0.20 |
| Inventory Turnover | 3.65 |
Taxes
In the past 12 months, Advent Pharma has paid 12.24 million in taxes.
| Income Tax | 12.24M |
| Effective Tax Rate | 23.94% |
Stock Price Statistics
The stock price has increased by +5.19% in the last 52 weeks. The beta is 0.27, so Advent Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.27 |
| 52-Week Price Change | +5.19% |
| 50-Day Moving Average | 13.53 |
| 200-Day Moving Average | 14.25 |
| Relative Strength Index (RSI) | 61.58 |
| Average Volume (20 Days) | 97,355 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Advent Pharma had revenue of BDT 401.85 million and earned 38.90 million in profits. Earnings per share was 0.42.
| Revenue | 401.85M |
| Gross Profit | 121.68M |
| Operating Income | 62.56M |
| Pretax Income | 51.14M |
| Net Income | 38.90M |
| EBITDA | 122.32M |
| EBIT | 62.56M |
| Earnings Per Share (EPS) | 0.42 |
Balance Sheet
The company has 445,425 in cash and 76.41 million in debt, with a net cash position of -75.97 million or -0.82 per share.
| Cash & Cash Equivalents | 445,425 |
| Total Debt | 76.41M |
| Net Cash | -75.97M |
| Net Cash Per Share | -0.82 |
| Equity (Book Value) | 1.57B |
| Book Value Per Share | 16.66 |
| Working Capital | 352.24M |
Cash Flow
In the last 12 months, operating cash flow was 14.38 million and capital expenditures -12.22 million, giving a free cash flow of 2.16 million.
| Operating Cash Flow | 14.38M |
| Capital Expenditures | -12.22M |
| Depreciation & Amortization | 59.76M |
| Net Borrowing | 619,682 |
| Free Cash Flow | 2.16M |
| FCF Per Share | 0.02 |
Margins
Gross margin is 30.28%, with operating and profit margins of 15.57% and 9.68%.
| Gross Margin | 30.28% |
| Operating Margin | 15.57% |
| Pretax Margin | 12.73% |
| Profit Margin | 9.68% |
| EBITDA Margin | 30.44% |
| EBIT Margin | 15.57% |
| FCF Margin | 0.54% |
Dividends & Yields
This stock pays an annual dividend of 0.05, which amounts to a dividend yield of 0.35%.
| Dividend Per Share | 0.05 |
| Dividend Yield | 0.35% |
| Dividend Growth (YoY) | -70.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 4.15% |
| FCF Payout Ratio | 64.67% |
| Buyback Yield | 0.28% |
| Shareholder Yield | 0.63% |
| Earnings Yield | 2.92% |
| FCF Yield | 0.16% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Stock Splits
The last stock split was on February 28, 2022. It was a forward split with a ratio of 1.02.
| Last Split Date | Feb 28, 2022 |
| Split Type | Forward |
| Split Ratio | 1.02 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |